This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Can Biotech ETFs Gain From Positive Booster Update?
by Sweta Jaiswal, FRM
In an effort to combat the coronavirus outbreak and accelerate the distribution process of extra doses in the United States, the FDA has approved the vaccine booster shots.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Stocks to Correct 5-10% in 2021? Buy These ETFs
by Sanghamitra Saha
Some market watchers are raising concerns about overvaluation in the market. Investors can thus bet on these undervalued but top-ranked ETFs.
5 Top ETFs With Great Value & More Room for Growth
by Sanghamitra Saha
The S&P 500 has been in a great shape this year, calling for overvaluation concerns. Why not investing in ETFs that have underperformed the S&P 500, have a lower P/E and have a Buy rating.
Best ETF Areas for Placing Your Bets in September
by Sweta Jaiswal, FRM
Let's take a look at some ETF areas that can be good investment options for September.
Top ETF Stories of August
by Sanghamitra Saha
Taper talks, the Senate approval of the infrastructure bill, upbeat earnings, FDA Approval for Pfizer COVID-19 Vaccine and recovery of China ETFs were the key highlights of the broader global markets in August.
Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs
by Sweta Jaiswal, FRM
The biotech space has once again come under the spotlight as the FDA has granted the first full U.S. approval to Pfizer (PFE)/BioNTech's (BNTX) coronavirus vaccine.
Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News
by Sweta Killa
The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.